A Phase 2 interventional study of MK0677 in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-07-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 2, and was the 2nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 8 more countries
Ages 50–85
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 9 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 34 across the 29 interventional studies, 11 across the 1 observational. Of the 29 that completed or were terminated, 20 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.
Cognitive function over 12 month period; safety and tolerability
Time frame: over 12 month period
AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.
Time frame: over a 6 month and 12 month period
No study locations are listed for this record.
The record gives a start of Oct 2003, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibutamoren